Job Watch

Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)

Funding Opportunity PAR-22-032 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-146 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.

Child Health Research Career Development Award (CHRCDA) Program (K12 Clinical Trial Not Allowed)

Funding Opportunity RFA-HD-23-010 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is to provide junior faculty pediatricians with state of the art training in an academic research setting to stimulate pediatric research over a variety of disciplines. The program provides supervised research career development opportunities to assist junior faculty in their transition to productive pediatrician scientists. The goal of the Child Health Research Career Development Award (CHRCDA) Program is to promote the performance of research and transfer of findings that will benefit the health of children. This will be accomplished by supporting research career development of new faculty-level pediatricians, to be known as CHRCDA Scholars. These K12 Program grant awards will generate well-qualified pediatrician scientists who will help meet the need for highly skilled physician investigators who can take advantage of new technologies and respond to the increasing demands of pediatric research.

EMBL: Java/Spring Software Engineer

New Scientist - Bioinformatics - Fri, 2021-11-26 03:54
Competitive Salary: EMBL: We are seeking a Java / Spring Software Engineer to join the IMPC project, at the European Bioinformatics Institute (EMBL-EBI) located at the Wellcome Hinxton, Cambridgeshire, England
Categories: Job Watch

EMBL: Head of Technical Services

New Scientist - Bioinformatics - Fri, 2021-11-26 03:52
Competitive Salary: EMBL: We are looking for an experienced technical leader to develop and implement the technology strategy for our world-leading bioinformatics centre, as we Hinxton, Cambridgeshire, England
Categories: Job Watch

EMBL: EMBL-EBI Grants Office Manager

New Scientist - Bioinformatics - Fri, 2021-11-26 03:52
Competitive Salary: EMBL: We have an exciting opportunity for a Grants Office Manager to lead our Grants team at EMBL's European Bioinformatics Institute (EMBL-EBI) based in Hi Hinxton, Cambridgeshire, England
Categories: Job Watch

EMBL: Business Intelligence Analyst

New Scientist - Bioinformatics - Fri, 2021-11-26 03:51
Competitive Salary: EMBL: EMBL's European Bioinformatics Institute (EMBL-EBI) is seeking a Business Intelligence Analyst to provide a data-driven approach to support decision m Hinxton, Cambridgeshire, England
Categories: Job Watch

Wellcome Sanger Institute: Senior Bioinformatician

New Scientist - Bioinformatics - Thu, 2021-11-25 11:51
£37,865-£45,359 per annum: Wellcome Sanger Institute:   Open Targets has launched Open Targets Genetics (https://genetics.opentargets.org), a portal that aggregates large scale GWAS data with functiona... Cambridge, Cambridgeshire (GB)
Categories: Job Watch

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: NGS Bioinformatician for Biomedical Sequencing Facility (m/f/d)

New Scientist - Bioinformatics - Thu, 2021-11-25 06:40
EUR 55,000 (the salary will reflect the successful candidate’s qualifications and can be higher): CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The Biomedical Sequencing Facility at the CeMM Research Center for Molecular Medicine of the.... Vienna, Austria
Categories: Job Watch

Centers for Agricultural Safety and Health (U54)

Funding Opportunity RFA-OH-22-002 from the NIH Guide for Grants and Contracts. The National Institute for Occupational Safety and Health (NIOSH) within the Centers for Disease Control and Prevention (CDC) invites applications for the Centers for Agricultural Safety and Health (Ag Centers). These centers are expected to conduct high quality research and subsequently disseminate their findings and recommendations in audience appropriate products to contribute to improving the safety and health of agriculture, forestry, and fishing workers. Center structure should take advantage of diverse scientific resources and focus on local, regional, and/or national worker safety and health issues. Emphasis should be placed on the creation and implementation of evidence-based solutions that address important agricultural, forestry, and fishing safety and health problems. Centers should also use innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based solutions. Collaborations with other academic institutions, nonprofit organizations, and other occupational safety and health focused groups are expected. Applicants must concisely describe the occupational safety and health burden within their service area and directly link research and outreach activities to help alleviate the burden. Applicants should also clearly articulate the anticipated impacts of the proposed work, both during the project period and beyond.

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Funding Opportunity RFA-CA-22-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Funding Opportunity RFA-CA-22-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Analysis, Technology, Leadership, Administration and Science (ATLAS) Center (U24 Clinical Trial Not Allowed)

Funding Opportunity RFA-DK-21-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement intends to support the creation of an Analysis, Technology, Leadership, And Science Center (ATLAS) that has the overarching goal of building the "go-to" open-access resource for the research community of mouse and human renal and genitourinary development and disease. The ATLAS Center will have scientific and administrative responsibilities including: 1) integrating and visualizing disparate datatypes and organs of the renal and genitourinary tract; 2) developing, adopting, or improving state-of-the-art computational tools and approaches to carry out analyses of multi-modal molecular and imaging data; 3) building interactive 2D/3D atlases and molecular maps with FAIR principles (findable, accessible, interoperable, and reusable) to promote data retrieval, exploration, discovery, and analysis by the community; 4) developing, designing, maintaining, and enhancing an open-access, interactive public data and analysis portal; and 5) coordinating internal and external activities of the GenitoUrinary Development Molecular Anatomy Project (GUDMAP) and (Re)Building a Kidney (RBK) consortia, including administration of an opportunity pool to address scientific gaps and opportunities.

Pages

Subscribe to Anil Jegga aggregator - Job Watch